MISSISSAUGA, ON, Oct. 11, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM),a drug development company advancing hematology and cancer related
products,today announced that the results of its Phase I/II Study of CYT387, a
JAK1/JAK2 inhibitor currently being evaluated for the treatment of
myelofibrosis, have been selected by the ASH Program Committee for
presentation in an Oral Session at the 2012 Annual Meeting of the
American Society of Hematology to be held in Atlanta, Georgia on
December 9, 2012.
"CYT387 could prove to be an important and differentiated therapeutic
for patients with myelofibrosis; the interim data we have reported to
date have been highly encouraging," said Dr. Nick Glover, President and
CEO of YM BioSciences. "We look forward to the release of final
nine-month data from the Phase I/II CYT387 study at ASH, as well as
further ongoing data from the many patients who continue to benefit
from the drug in its Extension trial."
Title: Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of
Myelofibrosis
Session Name: 634. Myeloproliferative Syndromes - Clinical: Myeloproliferative
Neoplasms - Novel Therapies I
Session Date: Sunday, December 9, 2012; 4:30 PM - 6:00 PM (Presentation Time: 5:15
PM)
Location: Georgia World Congress Center, Room B213-B214
About YM BioSciences
YM BioSciences Inc. is a drug development company primarily focused on
advancing CYT387, an orally administered inhibitor of both the JAK1 and
JAK2 kinases, which have been implicated in a number of hematological
and immune cell disorders including myeloproliferative neoplasms and
inflammatory diseases as well as certain cancers. Positive interim
results have been reported from a Phase I/II trial of CYT387 in 166
patients with myelofibrosis. YM's portfolio also includes nimotuzumab,
a humanized monoclonal antibody targeting EGFR with an enhanced
side-effect profile over currently marketed EGFR-targeting antibodies.
Nimotuzumab is being evaluated in numerous Phase II and III trials
worldwide. In addition, YM has several preclinical programs underway
with candidates from its library of novel compounds identified through
internal research conducted at YM BioSciences Australia.
This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may
cause actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by
such forward-looking statements. Such factors include, but are not
limited to, changing market conditions, the successful and timely
completion of clinical studies, the establishment of corporate
alliances, the impact of competitive products and pricing, new product
development, uncertainties related to the regulatory approval process
or the ability to obtain drug product in sufficient quantity or at
standards acceptable to health regulatory authorities to complete
clinical trials or to meet commercial demand; and other risks detailed
from time to time in the Company's ongoing quarterly and annual
reporting. Certain of the assumptions made in preparing forward-looking
statements include but are not limited to the following: that CYT387
and nimotuzumab will generate positive efficacy and safety data in
ongoing and future clinical trials, and that YM as well as CIMYM's
various licensees will complete their respective clinical trials and
disclose data within the timelines communicated in this release. Except
as required by applicable securities laws, we undertake no obligation
to publicly update or revise any forward-looking statements, whether as
a result of new information, future events or otherwise.
SOURCE YM BioSciences Inc.